Home » Interviews » Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)
Potential Treatment for COVID-19

Avacta Group Antigen distribution agreement and potential treatment for COVID-19 (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss a distribution agreement with Medusa 19 for its rapid antigen test direct to consumer. Alastair talks us through this latest news, provides an update on the development of the tests and provides details around the potential Affimer treatment for COVID 19.

Avacta Group’s Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal’s immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Did you know you can listen to our interviews on Spotify and ITunes, why not follow us to listen on the move.

Join us on our new LinkedIn page

Follow us on LinkedIn